James E Flynn Insider Trading $EMLR Talon Therapeutics, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in Talon Therapeutics, Inc.
Trading Symbol: EMLRIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: Director
Holdings: 0 shares
Latest Transaction: Jul 18 2013
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in Talon Therapeutics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 187,149 | 224,579 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 116,172 | 139,406 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 39,249 | 47,099 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 21,414 | 25,697 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 9,258 | 3,240 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 5,748 | 2,012 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 1,938 | 678 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 1,056 | 370 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 19,620 | 5,886 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 12,179 | 3,654 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 4,114 | 1,234 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,243 | 673 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 21,213 | 15,613 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 13,168 | 9,692 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 4,448 | 3,274 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 2,426 | 1,786 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 14,005,557 | 785,712 | 0 | 14 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 2,830,978 | 990,842 | 14,005,557 | 11.2 M to 14 M (+25.33 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 7,323,275 | 2,196,983 | 11,174,579 | 3.9 M to 11.2 M (+190.15 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 3,714,455 | 2,733,839 | 3,851,304 | 136.8 K to 3.9 M (+2,714.27 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 8,694,231 | 487,746 | 0 | 8.7 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 1,757,664 | 615,182 | 8,694,231 | 6.9 M to 8.7 M (+25.34 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 4,545,880 | 1,363,764 | 6,936,567 | 2.4 M to 6.9 M (+190.15 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 2,305,753 | 1,697,034 | 2,390,687 | 84.9 K to 2.4 M (+2,714.76 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 2,974,566 | 166,873 | 0 | 3 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 592,613 | 207,415 | 2,974,566 | 2.4 M to 3 M (+24.88 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 1,535,573 | 460,672 | 2,381,953 | 846.4 K to 2.4 M (+181.43 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 778,856 | 573,238 | 846,380 | 67.5 K to 846.4 K (+1,153.45 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 1,619,176 | 90,836 | 0 | 1.6 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 322,911 | 113,019 | 1,619,176 | 1.3 M to 1.6 M (+24.91 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 837,215 | 251,165 | 1,296,265 | 459.1 K to 1.3 M (+182.38 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 424,798 | 312,651 | 459,050 | 34.3 K to 459.1 K (+1,240.21 %) |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 3,086 | 1,080 | 9,258 | |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 1,916 | 671 | 5,748 | |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 646 | 226 | 1,938 | |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 352 | 123 | 1,056 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 1,543 | 540 | 6,172 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 958 | 335 | 3,832 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 323 | 113 | 1,292 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 176 | 62 | 704 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 3,510 | 1,053 | 0 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,179 | 654 | 0 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 736 | 221 | 0 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 401 | 120 | 0 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 3,510 | 1,053 | 19,620 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,179 | 654 | 12,179 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 736 | 221 | 4,114 | |
Oct 10 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 401 | 120 | 2,243 | |
Aug 21 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 3,086 | 1,080 | 4,629 | |
Aug 21 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 1,916 | 671 | 2,874 | |
Aug 21 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 646 | 226 | 969 | |
Aug 21 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 352 | 123 | 528 | |
Jul 09 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.22 | 228,392 | 278,638 | 136,849 | 365.2 K to 136.8 K (-62.53 %) |
Jul 09 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.22 | 141,750 | 172,935 | 84,934 | 226.7 K to 84.9 K (-62.53 %) |
Jul 09 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.22 | 112,693 | 137,485 | 67,524 | 180.2 K to 67.5 K (-62.53 %) |
Jul 09 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.22 | 57,165 | 69,741 | 34,252 | 91.4 K to 34.3 K (-62.53 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 1,543 | 540 | 1,543 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 958 | 335 | 958 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 323 | 113 | 323 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 176 | 62 | 176 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 3,472 | 1,042 | 1 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,155 | 647 | 1 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 728 | 218 | 1 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 397 | 119 | 1 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 3,472 | 1,042 | 16,110 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,155 | 647 | 10,000 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 728 | 218 | 3,378 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 397 | 119 | 1,842 | |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.33 | 283,180 | 376,629 | 299,811 | 583 K to 299.8 K (-48.57 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.33 | 175,782 | 233,790 | 186,037 | 361.8 K to 186 K (-48.58 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.33 | 59,388 | 78,986 | 252,561 | 311.9 K to 252.6 K (-19.04 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.33 | 32,402 | 43,095 | 125,150 | 157.6 K to 125.2 K (-20.57 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 85,623 | 102,748 | 582,991 | 668.6 K to 583 K (-12.81 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 53,150 | 63,780 | 361,819 | 415 K to 361.8 K (-12.81 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 17,957 | 21,548 | 311,949 | 329.9 K to 311.9 K (-5.44 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 9,797 | 11,756 | 157,552 | 167.3 K to 157.6 K (-5.85 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.14 | 82,321 | 93,846 | 668,614 | 750.9 K to 668.6 K (-10.96 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.14 | 51,091 | 58,244 | 414,969 | 466.1 K to 415 K (-10.96 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.14 | 40,619 | 46,306 | 329,906 | 370.5 K to 329.9 K (-10.96 %) |
Jul 03 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.14 | 20,604 | 23,489 | 167,349 | 188 K to 167.3 K (-10.96 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 3,472 | 1,042 | 1 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,155 | 647 | 1 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 728 | 218 | 1 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 397 | 119 | 1 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 3,472 | 1,042 | 12,638 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,155 | 647 | 7,845 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 728 | 218 | 2,650 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 397 | 119 | 1,445 | |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 27,500 | 26,950 | 919,426 | 946.9 K to 919.4 K (-2.90 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 70,184 | 69,482 | 946,926 | 1 M to 946.9 K (-6.90 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 17,123 | 16,781 | 570,632 | 587.8 K to 570.6 K (-2.91 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 43,600 | 43,164 | 587,755 | 631.4 K to 587.8 K (-6.91 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 11,900 | 11,662 | 453,663 | 465.6 K to 453.7 K (-2.56 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 30,400 | 30,096 | 465,563 | 496 K to 465.6 K (-6.13 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 8,577 | 8,405 | 230,125 | 238.7 K to 230.1 K (-3.59 %) |
May 07 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 21,816 | 21,598 | 238,702 | 260.5 K to 238.7 K (-8.37 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 92,964 | 99,471 | 750,935 | 843.9 K to 750.9 K (-11.02 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 57,697 | 61,736 | 466,060 | 523.8 K to 466.1 K (-11.02 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 45,871 | 49,082 | 370,525 | 416.4 K to 370.5 K (-11.02 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 23,268 | 24,897 | 187,953 | 211.2 K to 188 K (-11.02 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 49,170 | 49,170 | 843,899 | 893.1 K to 843.9 K (-5.51 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 30,517 | 30,517 | 523,757 | 554.3 K to 523.8 K (-5.51 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 24,262 | 24,262 | 416,396 | 440.7 K to 416.4 K (-5.51 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 12,307 | 12,307 | 211,221 | 223.5 K to 211.2 K (-5.51 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 26,357 | 25,830 | 893,069 | 919.4 K to 893.1 K (-2.87 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 16,358 | 16,031 | 554,274 | 570.6 K to 554.3 K (-2.87 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 13,005 | 12,745 | 440,658 | 453.7 K to 440.7 K (-2.87 %) |
Jun 28 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 6,597 | 6,465 | 223,528 | 230.1 K to 223.5 K (-2.87 %) |
Mar 23 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 48,600 | 51,030 | 1,017,110 | 1.1 M to 1 M (-4.56 %) |
Mar 23 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 30,226 | 31,737 | 631,355 | 661.6 K to 631.4 K (-4.57 %) |
Mar 23 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 21,074 | 22,128 | 495,963 | 517 K to 496 K (-4.08 %) |
Mar 23 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 15,100 | 15,855 | 260,518 | 275.6 K to 260.5 K (-5.48 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 15,025 | 15,175 | 1,065,710 | 1.1 M to 1.1 M (-1.39 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 9,326 | 9,419 | 661,581 | 670.9 K to 661.6 K (-1.39 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 7,290 | 7,363 | 517,037 | 524.3 K to 517 K (-1.39 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 3,885 | 3,924 | 275,618 | 279.5 K to 275.6 K (-1.39 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 7,824 | 8,137 | 1,080,735 | 1.1 M to 1.1 M (-0.72 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 4,857 | 5,051 | 670,907 | 675.8 K to 670.9 K (-0.72 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 3,796 | 3,948 | 524,327 | 528.1 K to 524.3 K (-0.72 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 2,023 | 2,104 | 279,503 | 281.5 K to 279.5 K (-0.72 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 52,094 | 57,824 | 1,088,559 | 1.1 M to 1.1 M (-4.57 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 32,339 | 35,896 | 675,764 | 708.1 K to 675.8 K (-4.57 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 25,275 | 28,055 | 528,123 | 553.4 K to 528.1 K (-4.57 %) |
Mar 14 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 13,472 | 14,954 | 281,526 | 295 K to 281.5 K (-4.57 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 64,706 | 77,647 | 1,140,653 | 1.2 M to 1.1 M (-5.37 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 40,167 | 48,200 | 708,103 | 748.3 K to 708.1 K (-5.37 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 31,393 | 37,672 | 553,398 | 584.8 K to 553.4 K (-5.37 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.20 | 16,734 | 20,081 | 294,998 | 311.7 K to 295 K (-5.37 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 23,261 | 24,191 | 1,205,359 | 1.2 M to 1.2 M (-1.89 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 14,439 | 15,017 | 748,270 | 762.7 K to 748.3 K (-1.89 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 11,285 | 11,736 | 584,791 | 596.1 K to 584.8 K (-1.89 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.04 | 6,015 | 6,256 | 311,732 | 317.7 K to 311.7 K (-1.89 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 8,881 | 8,792 | 1,228,620 | 1.2 M to 1.2 M (-0.72 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 5,513 | 5,458 | 762,709 | 768.2 K to 762.7 K (-0.72 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 4,310 | 4,267 | 596,076 | 600.4 K to 596.1 K (-0.72 %) |
Mar 12 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 2,296 | 2,273 | 317,747 | 320 K to 317.7 K (-0.72 %) |
Feb 08 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 10,600 | 10,388 | 1,237,501 | 1.2 M to 1.2 M (-0.85 %) |
Feb 08 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 6,536 | 6,405 | 768,222 | 774.8 K to 768.2 K (-0.84 %) |
Feb 08 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 4,564 | 4,473 | 600,386 | 605 K to 600.4 K (-0.75 %) |
Feb 08 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 3,300 | 3,234 | 320,043 | 323.3 K to 320 K (-1.02 %) |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.00 | 1 | 0 | 1 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.00 | 1 | 0 | 1 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.00 | 1 | 0 | 1 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.00 | 1 | 0 | 1 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.30 | 9,166 | 2,750 | 9,166 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.30 | 5,690 | 1,707 | 5,690 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.30 | 1,922 | 577 | 1,922 | |
Jan 11 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.30 | 1,048 | 314 | 1,048 | |
Sep 28 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 3,161 | 3,161 | 1,248,101 | 1.3 M to 1.2 M (-0.25 %) |
Sep 28 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 1,962 | 1,962 | 774,758 | 776.7 K to 774.8 K (-0.25 %) |